| Pair Name | Atractylenolide-III, Docetaxel | ||
| Phytochemical Name | Atractylenolide-III (PubChem CID: 155948 ) | ||
| Anticancer drug Name | Docetaxel (PubChem CID: 148124 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Atractylenolide-III, Docetaxel | |||
| Disease Info | [ICD-11: 2B72] | Gastric cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Expression | FGFR1 | hsa2260 |
| Down-regulation | Expression | FGFR2 | hsa2263 | |
| Down-regulation | Expression | FGFR4 | hsa2264 | |
| In Vitro Model | AGS | Gastric adenocarcinoma | Homo sapiens (Human) | CVCL_0139 |
| SGC-7901 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0520 | |
| Result | ATL and docetaxel treatment performed the synergistic effects on the inhibition of growth and induction of apoptosis in gastric cancer cells, and the underlying mechanism was mediated, at least partially, through the inhibition of FGFR1, -2, and -4. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Atractylenolide III Enhances the Anti-Neoplastic Efficacy of Docetaxel in Gastric Cancer Cell by Inhibiting Fibroblast Growth Factor Receptors 1, -2, and -4 Expression. J Environ Pathol Toxicol Oncol. 2019;38(3):217-227. doi: 10.1615/JEnvironPatholToxicolOncol.2019029196. | Click |
